New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
06:22 EDTINCYIncyte price target raised to $75 from $44 at Jefferies
Jefferies raised its price target for Incyte shares to $75 from $44 on expectations the company's IDO inhibitor with ipilimumab for melanoma could "unlock huge value." The firm says it heard positive commentary from four investigators involved in the Phase 2 study and keeps a Buy rating on the stock.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
17:06 EDTINCYIncyte publish Phase III RESPONSE trial results for polycythemia vera patients
Subscribe for More Information
08:10 EDTINCYIncyte receives orphan status for pancreatic cancer treatment
Subscribe for More Information
January 23, 2015
07:36 EDTINCYIncyte earns $25M milestone payment from Novartis for Jakavi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use